Polyrizon Signs Manufacturing Agreement with Eurofins CDMO for PL-14 Allergy Blocker Clinical Trial

Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, anno...

December 03, 2024 | Tuesday | News
Jasper Therapeutics Doses First Patient in Phase 1b/2a ETESIAN Study of Briquilimab for Allergic Asthma

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy t...

December 03, 2024 | Tuesday | News
Deepull Secures FDA Breakthrough Device Designation for Transformative Bloodstream Infection Test

deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced that it has receive...

December 02, 2024 | Monday | News
Taiwan’s Formosa Pharmaceuticals Partners with Medvisis to Launch Innovative Ophthalmic Treatment in Switzerland and Liechtenstein

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switze...

November 29, 2024 | Friday | News
European Commission Approves TEVIMBRA® for First-Line Treatment of Esophageal and Gastric Cancers

 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...

November 28, 2024 | Thursday | News
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Shows 96% Efficacy in Phase 3 PURPOSE 2 Trial

Gilead Sciences, Inc. (Nasdaq: GILD) announced The New England Journal of Medicine ( NEJM ) published the full results from the co...

November 28, 2024 | Thursday | News
European Commission Approves Single-Vial, Fully Liquid Menveo® Vaccine for Protection Against Meningococcal Disease

GSK plc (LSE/NYSE: GSK) announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococca...

November 28, 2024 | Thursday | News
Novartis Announces European Commission Approval of Kisqali® (ribociclib) for Adjuvant Treatment of High-Risk HR+/HER2- Early Breast Cancer

Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...

November 28, 2024 | Thursday | News
Adragos Pharma Acquires Baccinex, Strengthening Leadership in Aseptic Fill-Finish Across Europe, Japan, and Global Markets

Adragos Pharma, a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, has announced the acquisition of Baccinex, a...

November 27, 2024 | Wednesday | News
Hovione Expands Global Footprint with Major Investments in U.S. and Europe

    Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in...

November 27, 2024 | Wednesday | News
Roche to Acquire Poseida Therapeutics in Strategic Move to Advance Off-the-Shelf CAR-T Cell Therapies

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida&r...

November 27, 2024 | Wednesday | News
Alnylam's Vutrisiran sNDA Accepted by FDA for Priority Review in ATTR-CM with March 2025 Decision Expected

 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration&n...

November 26, 2024 | Tuesday | News
GSK’s Blenrep Combination Therapy Accepted for FDA Review in Relapsed Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep&...

November 26, 2024 | Tuesday | News
Kedrion Biopharma's Bolognana Facility FDA-Approved to Manufacture RYPLAZIM® for PLGD-1 Treatment

 Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in B...

November 22, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close